Medically reviewed by Jessica Swirble, PharmDLast updated on April 4, 2025
Drug Information| |
Atomoxetine is a medication prescribed to treat attention deficit hyperactivity disorder (ADHD) in children with conduct disorder. It is available as an injection and tablet in the brand name Strattera.
Atomoxetine is an antidepressant. It works by increasing the levels of norepinephrine and dopamine in the brain. This increase in dopamine levels helps improve attention, impulse control, and behavior
Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI). It works by increasing the amount of norepinephrine in the brain. This reabsorption allows norepinephrine to be sent to the nerves in the brain to help with focus and/or impulse control.
Please note that the safety and effectiveness of this medication have not been established when the use is done in quantities greater than 100 mg per day.
The information provided on This service is intended for educational purposes only and should not be a substitute for professional medical advice. You should consult your doctor and read the medication guide for a list of treatments. If you have any questions or concerns, please talk to you.
For more information on this medication, see. FirigipThis product requires a prescription.
This service is not licensed to prescribe or offer any other medications. Please consult your doctor or pharmacist for a list of medications and proper use. In addition, For Additional information about becoming a patient, please visit This page.
|
| For More Information
There are several reasons why it may be necessary to treat attention deficit disorder (ADHD). ADHD is a core condition that can lead to poor academic and occupational performance. It can also cause behavioural changes, such as behavioural change, in children who are diagnosed with ADHD.
ADHD can present with symptoms such as difficulty paying attention, being restless, being unable to remain awake and being irritable, aggressive and irritable. It may also present with symptoms such as anxiety, agitation, difficulty sleeping, irritability and irritability.
The symptoms of ADHD may include difficulty paying attention, being restless, being unable to sleep or being irritable and aggressive. They may also present with symptoms such as anxiety, agitation, difficulty sleeping, irritability and irritability.
Treatment for ADHD typically involves medication, such as stimulants, in order to increase attention. ADHD medication is often prescribed in combination with other treatments, such as therapy, in order to improve symptoms of ADHD.
It is important to note that not all people diagnosed with ADHD will benefit from medications, and some may require additional support or treatment. You and your doctor can talk about the benefits and risks of using this medication.
| Class - T| Description | |
Low | |
No medication guidance |
This service is available only after an online consultation with a licensed physician. Our U. S.
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
This product is temporarily unavailable.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
pharmacy24xKe & Co. Ke & Co.ATLANTA--AP ©izar no! It’s a bad idea for a drug company to sell it to the U. S. market. But the company has come up with the idea, and it will be available in the U. soon, the company said.
The Food and Drug Administration (FDA) is considering the idea and is waiting to see if the FDA approves it. (We have some more information: “The FDA is not in favor of sales of prescription drugs.”)
According to, the drug company has been working to get the drug to the U. A letter of approval for its generic drug, Strattera, will be sent out online by the FDA this week. The letter will describe the process and, if approved, will determine whether the drug has the desired effect.
“Our goal is to get approval from the FDA for the generic form of Strattera and for the generic form of atomoxetine,” said, the company’s senior vice president of marketing. “We’ve got to get in the way of that approval. We want to keep working on that.”
Strattera is manufactured by Eli Lilly and is the generic version of Atomoxetine. It is the second-biggest generic drug to be approved for the treatment of ADHD in the United States. (The U. market is projected to be worth $3.8 billion this year.)
Strattera has been approved for marketing to the U. Strattera sales are projected to exceed $2.1 billion in 2005, according to IMS Health. The drug is being used as a treatment for ADHD, according to the IMS report.
In January, the FDA approved a drug for the treatment of attention deficit disorder and narcolepsy. The agency also approved a drug for the treatment of narcolepsy, according to the FDA. The drug is already being marketed as a treatment for narcolepsy, and it is already sold at much higher prices than those offered by Eli Lilly.
In December 2005, the FDA approved a drug for the treatment of attention deficit disorder. The agency also approved a drug for narcolepsy, and in February 2005, the FDA approved a drug for narcolepsy, according to the FDA.
Strattera is also being marketed as a drug for attention deficit disorder. The company will market the drug in the U. for the treatment of ADHD.
The FDA has approved Strattera for the treatment of attention deficit hyperactivity disorder. The FDA has approved the drug for the treatment of narcolepsy. The FDA is also approved to treat attention deficit hyperactivity disorder.
A generic drug is an approved medication for a disorder that affects multiple systems. It can have several causes and symptoms. These can include:Strattera is approved for marketing in the U. and Canada.
According to the FDA, it was approved for marketing in the U. by the pharmaceutical company Eli Lilly. Eli Lilly’s drug, Adderall, is the generic version of Strattera.
Lilly will continue to market Strattera to its Canadian customers, though the FDA has not approved it for the treatment of ADHD.
Strattera (atomoxetine) is prescribed for the management of attention deficit hyperactivity disorder (ADHD) in children and adolescents. It works by increasing the levels of norepinephrine in the brain, which can help reduce impulsivity and improve attention span and focus. ADHD can be divided into two main groups, ADHD and narcolepsy. The first group has a high prevalence of ADHD, while the second group is more common in young people. The second group is also treated with an atypical antipsychotic and an antiepileptic drug, which can help reduce the symptoms of ADHD. In adults, Strattera is prescribed for attention deficit hyperactivity disorder (ADHD) for the first time, but it is not approved for use in children. Strattera is often used as part of a comprehensive treatment program. It is indicated for treating attention deficit disorder (ADHD) in children and adolescents and as an adjunct to other treatment methods.
Strattera (atomoxetine)Atomoxetine, a selective norepinephrine reuptake inhibitor, has been studied as an antipsychotic for ADHD. The primary aim of this study was to compare Strattera with placebo in children and adolescents. Secondary aim was to compare Strattera with placebo in children and adolescents treated with an atypical antipsychotic. Inclusion and exclusion criteria were as follows: 1. Children and adolescents: 1 month to 6 years of age with ADHD, 2. Severely hypocaloric ADHD, 3. Severely co-occurring ADHD, 4. Mild to moderate co-morbid ADHD. 3. Controlled clinical trials: Strattera vs placebo, 4. Randomized controlled trials, 6. Inclusion criteria: 1. Children and adolescents: 2 to 5 years of age, 3. Severely hypocaloric ADHD, 4. Severe co-morbid ADHD, 5. Mild to moderate co-occurring ADHD, 6. Controlled clinical trials: Strattera vs placebo, 7. Randomized controlled trials, 8. Children and adolescents: 1 year to 5 years of age, 2. Severe co-occurring ADHD, 4. Mild to moderate co-occurring ADHD, 5. Controlled clinical trials: Strattera vs placebo, 9. Randomized controlled trials, 10. Inclusion criteria: 2. Children and adolescents: 6 years to 12 years of age, 7 to 9 years of age, 10. Severely hypocaloric ADHD, 11. Severe co-occurring ADHD, 12. Mild to moderate co-occurring ADHD, 13. Controlled clinical trials: Strattera vs placebo, 14. Randomized controlled trials, 15. Inclusion criteria: 3. Children and adolescents: 8 years to 20 years of age, 16 years of age, 17 years of age, 18 years of age, 19 years of age, 20 years of age, and 21 years of age. 4. Children and adolescents: 12 years to 65 years of age, 65 years of age, and older, and over 65 years of age.
Strattera is used in the treatment of ADHD in children and adolescents who are clinically diagnosed as having an impaired response to a stimulant drug, or for whom a stimulant is contraindicated. The medication should be prescribed under the supervision of a physician.
The mechanism of action for atomoxetine is to increase the norepinephrine levels, which can help reduce impulsivity and improve attention span and focus. Atomoxetine is not recommended in children and adolescents with ADHD who are not responding well to stimulants. It is not effective for the treatment of ADHD in the absence of underlying organic problems.The pharmacological approach to ADHD treatment is not to start a medication within 24 hours, but to start a medication within 48 to 72 hours to treat symptoms and to avoid withdrawal symptoms. Atomoxetine should be taken in the dose and schedule as directed by the physician.
Strattera may not be suitable for all patients, so the use of a different dose and schedule of atomoxetine is recommended. The treatment regimen of atomoxetine is to be initiated at a dose of 100 mg three times a day for three consecutive days. If the patient does not respond to the dose or schedule of atomoxetine, a second dose should be started on the third day of the week, followed by a maintenance dose of 20 mg per day.
Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$18.95
This product is temporarily unavailable.
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
Stade de France Pharmacy